Apreo Health has raised $130 million in a Series B financing round, led by Bain Capital Life Sciences and Norwest, to support pivotal trial and commercialization of its airway scaffold for severe emphysema.

Aug 07, 2025•4 months ago

Amount Raised

$130 Million

Round Type

series b

Menlo Parkmedical devicesMedicalBiotechnologyHealth Care

Investors

Santé VenturesLightstone VenturesIntuitive VenturesF PrimeNorwestBain Capital Life Sciences

Description

Apreo Health, a clinical-stage medical device company, announced the closing of an oversubscribed $130 million Series B financing round. The funding will support the BREATHE-3 trial, aimed at evaluating the safety and efficacy of their airway scaffold. New investors included Bain Capital Life Sciences and Norwest, with participation from others. This financing represents a significant milestone for the development of innovative treatments for severe emphysema.

Company Information

Company

Apreo Health

Location

4040 Campbell Ave

Menlo Park, California, United States

About

Apreo Health is redefining interventional pulmonology with a non-destructive, tissue-sparing solution for severe emphysema—one of the most under-treated and misunderstood diseases in medicine. Formed at The Foundry, one of the world’s premier medtech incubators, and backed by top-tier investors, Apreo is led by a team with deep expertise in both pulmonary medicine and medical device innovation. The company is advancing a therapy purpose-built to expand access, simplify delivery, and transform the treatment pathway for patients with severe emphysema.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends